Dimensional Fund Advisors
XLO icon

Dimensional Fund Advisors’s Xilio Therapeutics XLO Stock Holding History

Dimensional Fund Advisors’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,889
Closed -$55.8K – 3461
2023
Q3 		$55.8K Buy
1,889
+612
+48% +$22.8K ﹤0.01% 3370
2023
Q2 		$46.8K Hold
1,277
– – ﹤0.01% 3410
2023
Q1 		$56.9K Buy
+1,277
New +$56.1K ﹤0.01% 3373

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors's XLO Position: Q4 2023 in Review

Dimensional Fund Advisors sold out of Xilio Therapeutics (XLO) in Q4 2023, closing a stake of 1,889 shares — an estimated $55.8K sold.

Dimensional Fund Advisors first reported a position in XLO in Q1 2023 and held it in 3 quarters. The position peaked at $56.9K in Q1 2023. 33 funds tracked by Wall St. Rank hold XLO as of Q4 2023.

  • Dimensional Fund Advisors reported no remaining Xilio Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Dimensional Fund Advisors sold 1,889 Xilio Therapeutics shares in Q4 2023, an estimated $55.8K.
  • Dimensional Fund Advisors first reported a position in Xilio Therapeutics in Q1 2023 and held it in 3 quarters.
  • Dimensional Fund Advisors's Xilio Therapeutics position peaked at $56.9K in Q1 2023.
  • 33 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q4 2023.

Based on Dimensional Fund Advisors's 13F filing for Q4 2023, filed 7 Feb 2024.